Altre lingue SSY Group Limited

Azioni

2005

KYG8406X1034

Mercato chiuso - Hong Kong S.E. Altri mercati azionari 10:08:16 02/05/2024			Variaz. 5gg	Var. 1 gen.
4,7 ^HKD	-1,67%		+0,21%	-4,86%

16/04	Il Gruppo SSY registra un aumento di quasi il 15% nell'utile del primo trimestre	MT
08/04	Il Gruppo SSY fornisce aggiornamenti sui farmaci per l'infezione respiratoria e l'ipertensione	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

SSY Group Get Production, Registration Approval for Pneumonia Drug from Chinese Regulator	23/04
SSY Group Logs Nearly 15% Boost in Q1 Profit	16/04
SSY Group Provides Updates on Respiratory Infection, Hypertension Drugs	08/04
SSY Group Limited Announces Update on Product Development	08/04
SSY Group's Two Drugs Get China's NMPA's Nod for Production and Registration	03/04
SSY Group Limited Provides Update on Product Development	03/04
SSY Group's Profit Jumps 17% in 2023	27/03
SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024	27/03
SSY Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
SSY Group Obtains Drug Administration Approval for Diabetes Drug	25/03
SSY Gets Registration Approval for Parkinson’s Drug from Chinese Regulator	20/03
SSY Group Limited Announces Update on Product Development	20/03
SSY Group Gets Bulk Drug Approval from Chinese Authorities	01/03
SSY Group’s Angina Drug Gets Production, Registration Go-Ahead from Chinese Regulator	01/03
SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection from the National Medical Products Administration of China	01/03
SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market	29/02
SSY Group’s Blood Sugar Level Drug Passes Chinese Regulator’s Quality and Efficacy Consistency Evaluation	27/02
SSY Group Limited Receives Approval for Gliclazide Tablet	27/02
China Gives Drug Production Nod to SSY's Sodium Bicarbonate Ringer's Injection	23/02
SSY Group Limited Provides Update on Product Development	23/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue SSY Group Limited

Azioni

2005

KYG8406X1034

Altre lingue

Filtri